Our findings will provide greater insights into the molecular mechanisms underlying the TBI-associated AD and ADRD, and the potential development of novel therapeutics targeting BAG3 for preventing and treating TBI and TBI-associated AD and ADRD. This evidence concerns the gene BAG3 and Alzheimer disease.